story of the week
Outcomes of Trastuzumab–Deruxtecan Therapy in Patients With HER2+ Breast Cancer and Active Brain Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neuro-Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FINAL outcome ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-positive breast cancer PATIENTS WITH active brain metastases
Neuro-oncology 2024 Jul 04;[EPub Ahead of Print], R Bartsch, AS Berghoff, J Furtner, M Marhold, ES Bergen, S Roider-Schur, MJ Mair, AM Starzer, H Forstner, B Rottenmanner, MB Aretin, K Dieckmann, Z Bago-Horvath, H Haslacher, G Widhalm, A Ilhan-Mutlu, C Minichsdorfer, T Fuereder, T Szekeres, L Oehler, B Gruenberger, G Pfeiler, C Singer, A Weltermann, L Berchtold, M PreusserFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.